<head>
<title>Core Laboratories N.V. 8K Earnings Release</title>
</head>

<html>

<body>

<b><font SIZE="2">
</font><font SIZE="4">
<p ALIGN="CENTER">UNITED STATES</p>
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION</p>
</font><font SIZE="2">
<p ALIGN="CENTER">Washington, D.C. 20549</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">________________</p>
</font><b><font SIZE="5">
<p ALIGN="CENTER">FORM 8-K</p>
</font></b>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="684">
  <tr>
    <td VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">
      <p>CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934</font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">Date of report (Date of earliest event reported):<b>
      October 26, 2005</b></font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
</font><b><font FACE="Times" SIZE="5">
<p ALIGN="CENTER">CORE LABORATORIES N.V.</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">(Exact name of Registrant as specified in its charter)</p>
<p ALIGN="CENTER">Commission File Number 001-14273</p>
<p ALIGN="CENTER">&nbsp;</p>
</font>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680">
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(State or other jurisdiction of Incorporation or
      organization)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(I.R.S. Employer Identification No.)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Herengracht 424</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">1017 BZ Amsterdam</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Address of principal executive offices)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Zip Code)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p ALIGN="CENTER">Registrant's telephone number, including area code: <b>(31-20)
420-3191</p>
</b>
<p ALIGN="CENTER">&nbsp;</p>
<hr>
<p>&nbsp;</p>
<b>
<p>Item 2.02 Results of Operations and Financial Condition</p>
</b>
<p>On October 26, 2005, Core Laboratories N.V. issued a press release
announcing its 2005 second quarter financial results. The
full text of the press release is set forth in Exhibit 99 attached hereto and is
incorporated in this Report as if fully set forth herein.</p>
<p><font face="Times New Roman" size="2">In addition to financial results
determined in accordance with generally accepted accounting principles (GAAP)
that are included in the attached press release, these documents also include
the following non-GAAP financial measures (as defined under the SEC's
Regulation&nbsp;G): </font></p>
<div align="center">
  <center>
  <table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse" bordercolor="#111111" width="100%" id="AutoNumber1" height="236">
    <tr>
      <td width="5%" height="19">&nbsp;</td>
      <td width="4%" align="center" height="19" valign="top"><font size="2">*</font></td>
      <td width="91%" height="19"><b><font size="2">Income from Continuing
      Operations before Equity Based Stock Compensation Expenses &amp; Effective Tax
      Rate before Equity Based Stock Compensation Expenses:</font></b><font face="Times New Roman" size="2"><b><i>
      </i></b> </font><font size="2">Management believes that the exclusion of
      certain expenses and credits enables it to evaluate more effectively the
      Company's operations period over period and to identify operating trends
      that could otherwise be masked by the excluded items.</font></td>
    </tr>
    <tr>
      <td width="5%" height="8"><font size="1">&nbsp;</font></td>
      <td width="4%" align="center" height="8" valign="top"><font size="1">&nbsp;</font></td>
      <td width="91%" height="8"><font size="2">&nbsp;&nbsp; </font></td>
    </tr>
    <tr>
      <td width="5%" height="19">&nbsp;</td>
      <td width="4%" align="center" height="19" valign="top">*</td>
      <td width="91%" height="19"><b><font size="2">Incremental Operating
      Margins:</font></b><font size="2">Incremental operating margins is
      computed as (1) the increase or decrease in income from continuing
      operations before interest expense and income tax expense between two
      periods, divided by (2) the increase or decrease in revenues between the
      same two periods. Management believes that incremental margins provide
      useful information regarding the growth over the two periods being
      compared.</font></td>
    </tr>
    <tr>
      <td width="5%" height="8"><font size="1">&nbsp;</font></td>
      <td width="4%" align="center" height="8" valign="top"><font size="1">&nbsp;</font></td>
      <td width="91%" height="8"><font size="2">&nbsp;&nbsp; </font></td>
    </tr>
    <tr>
      <td width="5%" height="19">&nbsp;</td>
      <td width="4%" align="center" height="19" valign="top">*</td>
      <td width="91%" height="19"><b><font size="2">Free Cash Flow:</font></b><font face="Times New Roman" size="2"> </font>
      <font size="2">Free cash flow is an important measurement as it represents
      the cash from operations, in excess of capital expenditures, available to
      operate the business and fund non-discretionary obligations.</font></td>
    </tr>
    <tr>
      <td width="5%" height="8"><font size="1">&nbsp;</font></td>
      <td width="4%" align="center" height="8" valign="top"><font size="1">&nbsp;</font></td>
      <td width="91%" height="8"><font size="2">&nbsp;&nbsp; </font></td>
    </tr>
    <tr>
      <td width="5%" height="19">&nbsp;</td>
      <td width="4%" align="center" height="19" valign="top">*</td>
      <td width="91%" height="19"><b><font size="2">Days Sales Outstanding:</font></b><font face="Times New Roman" size="2"> </font>
      <font size="2">Days-sales-outstanding is determined by dividing the
      current balance in accounts receivable by annual or annualized revenue
      multiplied by 360 days. This is a common method of gauging how quickly
      collections are being made on accounts receivable.</font><font face="Times New Roman" size="2"> </font></td>
    </tr>
    <tr>
      <td width="5%" height="8"><font size="1">&nbsp;</font></td>
      <td width="4%" align="center" height="8" valign="top"><font size="1">&nbsp;</font></td>
      <td width="91%" height="8"><font size="2">&nbsp;&nbsp; </font></td>
    </tr>
    <tr>
      <td width="5%" height="19">&nbsp;</td>
      <td width="4%" align="center" height="19" valign="top">*</td>
      <td width="91%" height="19"><b><font size="2">Inventory Turnover:</font></b><font face="Times New Roman" size="2">
      </font><font size="2">Inventory turnover is annual or annualized cost of
      sales divided by the inventory balance all divided by 360 days. This is an
      important tool for Management to gauge how quickly inventory is being
      sold.</font><font face="Times New Roman" size="2">
      </font></td>
    </tr>
    <tr>
      <td width="5%" height="8"><font size="1">&nbsp;</font></td>
      <td width="4%" align="center" height="8" valign="top"><font size="1">&nbsp;</font></td>
      <td width="91%" height="8"><font size="2">&nbsp;&nbsp; </font></td>
    </tr>
    <tr>
      <td width="5%" height="19">&nbsp;</td>
      <td width="4%" align="center" height="19" valign="top">*</td>
      <td width="91%" height="19"><b><font size="2">Net Debt-to-Capital: </font>
      </b><font size="2">Net debt-to-capital is calculated as long-term debt
      less cash divided by shareholders' equity plus long-term debt. Management
      believes this capital structure ratio can provide a more accurate view of
      a company's long-term leverage and risk, since it considers only long-term
      debt and capital.</font></td>
    </tr>
    <tr>
      <td width="5%" height="8"><font size="1">&nbsp;</font></td>
      <td width="4%" align="center" height="8" valign="top"><font size="1">&nbsp;</font></td>
      <td width="91%" height="8"><font size="2">&nbsp;&nbsp; </font></td>
    </tr>
    <tr>
      <td width="5%" height="19">&nbsp;</td>
      <td width="4%" align="center" height="19" valign="top">*</td>
      <td width="91%" height="19"><b><font size="2">Return on Equity: </font>
      </b><font size="2">The calculation for return on equity is earnings before
      interest expense and tax expense divided by shareholders' equity.
      Management utilizes return on equity in evaluating how much profit the
      Company generates with the money shareholders have invested and is useful
      for comparing the profitability of companies in the same industry.</font></td>
    </tr>
    <tr>
      <td width="5%" height="8"><font size="1">&nbsp;</font></td>
      <td width="4%" align="center" height="8" valign="top"><font size="1">&nbsp;</font></td>
      <td width="91%" height="8"><font size="1">&nbsp;&nbsp; </font></td>
    </tr>
    </table>
  </center>
</div>
<p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">&nbsp;</p>
<p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">
<font face="Times New Roman" size="2">The foregoing non-GAAP financial measures
should be considered in addition to, not as a substitute for, or superior to,
net income, cash flows or other measures of financial performance prepared in
accordance with GAAP as more fully discussed in Core Laboratories financial
statements and filings with the Securities and Exchange Commission. </font></p>
<p>The information in this Form 8-K shall not be deemed &quot;filed&quot; for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section. The information in this
Current Report shall not be incorporated by reference into any registration
statement pursuant to the Securities Act of 1933, as amended.</p>
</font>
<div align="left">
<table CELLSPACING="0" BORDER="0" WIDTH="625" cellpadding="0">
  <tr>
    <td WIDTH="4%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="4%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="RIGHT">(a)</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="91%" VALIGN="MIDDLE">
      <p><font size="2">Public announcement or release, filed as an exhibit to
      this Current Report on Form 8-K</font></td>
  </tr>
  </table>
</div>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" WIDTH="514" cellpadding="0">
  <tr>
    <td WIDTH="15%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="84%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="15%" VALIGN="TOP"><font SIZE="2">
      <p>Exhibit 99</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="84%" VALIGN="TOP"><font SIZE="2">
      <p>Press release dated October 27, 2005.</font></td>
  </tr>
</table>
  </center>
</div>
</center>
<font SIZE="2">
<b>
<p ALIGN="CENTER">SIGNATURES</b></p>
<p>Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
</font>
<center>
<div align="right">
<table BORDER="0" CELLSPACING="0" WIDTH="635" cellpadding="0">
  <tr>
    <td WIDTH="47%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="48%" VALIGN="TOP" COLSPAN="5"><font SIZE="2">
      <p>Core Laboratories N.V.</font></td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP"><font SIZE="2">
      <p>Dated: October 28, 2005</font></td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP"><font SIZE="2">
      <p>By</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p style="border-bottom-style: solid; border-bottom-width: 1">/s/ Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p>Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p>Chief Financial Officer</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
</table>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<hr>
</font>
<b><font SIZE="2">
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION<br>
Washington, D.C. 20549</font></b></p>
<font SIZE="2"><b>
<p ALIGN="CENTER">CORE LABORATORIES N.V.<br>
EXHIBIT INDEX TO FORM 8-K</b></p>
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>
</font>
<center>
<div align="left">
<table CELLSPACING="0" BORDER="0" WIDTH="570" cellpadding="0">
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p>EXHIBIT NO.</font></b></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p>ITEM</font></b></td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="TOP"><font SIZE="2">
      <p>99</font></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP"><font SIZE="2">
      <p>Press Release dated October 27, 2005</font></td>
  </tr>
</table>
</div>
</center>
<p ALIGN="left">&nbsp;</p>

</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "clb-8k_earnrelease.htm", "description": "8K", "secsgml_size_bytes": 17008}]
{"company-data": {"conformed-name": "CORE LABORATORIES N V", "cik": "0001000229", "assigned-sic": "1389", "irs-number": "000000000", "state-of-incorporation": "P7", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14273", "film-number": "051164975"}, "business-address": {"street1": "1017 BZ AMSTERDAM", "street2": "HERENGRACHT 424", "city": "THE NETHERLANDS", "state": "P7", "phone": "3124203191"}, "mail-address": {"street1": "6316 WINDFERN", "city": "HOUSTON", "state": "TX", "zip": "77040"}}
Core Laboratories N.V. 8K Earnings Release
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
October 26, 2005
CORE LABORATORIES N.V.
(Exact name of Registrant as specified in its charter)
Commission File Number 001-14273
The Netherlands
Not Applicable
(State or other jurisdiction of Incorporation or
      organization)
(I.R.S. Employer Identification No.)
Herengracht 424
1017 BZ Amsterdam
The Netherlands
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(31-20)
420-3191
Item 2.02 Results of Operations and Financial Condition
On October 26, 2005, Core Laboratories N.V. issued a press release
announcing its 2005 second quarter financial results. The
full text of the press release is set forth in Exhibit 99 attached hereto and is
incorporated in this Report as if fully set forth herein.
In addition to financial results
determined in accordance with generally accepted accounting principles (GAAP)
that are included in the attached press release, these documents also include
the following non-GAAP financial measures (as defined under the SEC's
Regulation G):
*
Income from Continuing
      Operations before Equity Based Stock Compensation Expenses & Effective Tax
      Rate before Equity Based Stock Compensation Expenses:
Management believes that the exclusion of
      certain expenses and credits enables it to evaluate more effectively the
      Company's operations period over period and to identify operating trends
      that could otherwise be masked by the excluded items.
*
Incremental Operating
      Margins:
Incremental operating margins is
      computed as (1) the increase or decrease in income from continuing
      operations before interest expense and income tax expense between two
      periods, divided by (2) the increase or decrease in revenues between the
      same two periods. Management believes that incremental margins provide
      useful information regarding the growth over the two periods being
      compared.
*
Free Cash Flow:
Free cash flow is an important measurement as it represents
      the cash from operations, in excess of capital expenditures, available to
      operate the business and fund non-discretionary obligations.
*
Days Sales Outstanding:
Days-sales-outstanding is determined by dividing the
      current balance in accounts receivable by annual or annualized revenue
      multiplied by 360 days. This is a common method of gauging how quickly
      collections are being made on accounts receivable.
*
Inventory Turnover:
Inventory turnover is annual or annualized cost of
      sales divided by the inventory balance all divided by 360 days. This is an
      important tool for Management to gauge how quickly inventory is being
      sold.
*
Net Debt-to-Capital:
Net debt-to-capital is calculated as long-term debt
      less cash divided by shareholders' equity plus long-term debt. Management
      believes this capital structure ratio can provide a more accurate view of
      a company's long-term leverage and risk, since it considers only long-term
      debt and capital.
*
Return on Equity:
The calculation for return on equity is earnings before
      interest expense and tax expense divided by shareholders' equity.
      Management utilizes return on equity in evaluating how much profit the
      Company generates with the money shareholders have invested and is useful
      for comparing the profitability of companies in the same industry.
The foregoing non-GAAP financial measures
should be considered in addition to, not as a substitute for, or superior to,
net income, cash flows or other measures of financial performance prepared in
accordance with GAAP as more fully discussed in Core Laboratories financial
statements and filings with the Securities and Exchange Commission.
The information in this Form 8-K shall not be deemed "filed" for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section. The information in this
Current Report shall not be incorporated by reference into any registration
statement pursuant to the Securities Act of 1933, as amended.
(a)
Public announcement or release, filed as an exhibit to
      this Current Report on Form 8-K
Exhibit 99
Press release dated October 27, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Core Laboratories N.V.
Dated: October 28, 2005
By
/s/ Richard L. Bergmark
Richard L. Bergmark
Chief Financial Officer
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CORE LABORATORIES N.V.
EXHIBIT INDEX TO FORM 8-K
EXHIBIT NO.
ITEM
99
Press Release dated October 27, 2005